Asia Beat: Takeda + Nycomed = panic buy or strategic masterstroke?
This article was originally published in Scrip
Executive Summary
If anyone had any doubts that Takeda was going to sit on its hands while its multi-billion dollar top seller loses exclusivity, these should now have been well and truly put to rest.